These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 27831830)

  • 1. Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival?
    Sahu S; Schernthaner R; Ardon R; Chapiro J; Zhao Y; Sohn JH; Fleckenstein F; Lin M; Geschwind JF; Duran R
    Radiology; 2017 Jun; 283(3):883-894. PubMed ID: 27831830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.
    Tacher V; Lin M; Duran R; Yarmohammadi H; Lee H; Chapiro J; Chao M; Wang Z; Frangakis C; Sohn JH; Maltenfort MG; Pawlik T; Geschwind JF
    Radiology; 2016 Jan; 278(1):275-84. PubMed ID: 26131913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Volumetric Enhancing Tumor Burden at CT to Predict Survival Outcomes in Patients with Neuroendocrine Liver Metastases after Intra-arterial Treatment.
    Assouline J; Cannella R; Porrello G; de Mestier L; Dioguardi Burgio M; Raynaud L; Hentic O; Cros J; Tselikas L; Ruszniewski P; Vullierme MP; Vilgrain V; Duran R; Ronot M
    Radiol Imaging Cancer; 2023 Jan; 5(1):e220051. PubMed ID: 36607243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers.
    Chapiro J; Duran R; Lin M; Schernthaner RE; Wang Z; Gorodetski B; Geschwind JF
    Radiology; 2015 May; 275(2):438-47. PubMed ID: 25531387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
    Zhao Y; Duran R; Bai W; Sahu S; Wang W; Kabus S; Lin M; Han G; Geschwind JF
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):433-442. PubMed ID: 29086058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial chemoembolization in soft-tissue sarcoma metastases to the liver - the use of imaging biomarkers as predictors of patient survival.
    Chapiro J; Duran R; Lin M; Mungo B; Schlachter T; Schernthaner R; Gorodetski B; Wang Z; Geschwind JF
    Eur J Radiol; 2015 Mar; 84(3):424-430. PubMed ID: 25542065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models.
    Shim JH; Lee HC; Kim SO; Shin YM; Kim KM; Lim YS; Suh DJ
    Radiology; 2012 Feb; 262(2):708-18. PubMed ID: 22187634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
    Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
    J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Jung ES; Kim JH; Yoon EL; Lee HJ; Lee SJ; Suh SJ; Lee BJ; Seo YS; Yim HJ; Seo TS; Lee CH; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
    J Hepatol; 2013 Jun; 58(6):1181-7. PubMed ID: 23395691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome.
    Vandecaveye V; Michielsen K; De Keyzer F; Laleman W; Komuta M; Op de beeck K; Roskams T; Nevens F; Verslype C; Maleux G
    Radiology; 2014 Mar; 270(3):747-57. PubMed ID: 24475816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.
    Liu L; Wang W; Chen H; Zhao Y; Bai W; Yin Z; He C; Jia J; Yang M; Xia J; Fan D; Han G
    Clin Cancer Res; 2014 Mar; 20(6):1623-31. PubMed ID: 24493832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.
    Bonekamp S; Halappa VG; Geschwind JF; Li Z; Corona-Villalobos CP; Reyes D; Bhagat N; Cosgrove DP; Pawlik TM; Mezey E; Eng J; Kamel IR
    Radiology; 2013 Aug; 268(2):431-9. PubMed ID: 23616632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
    Prajapati HJ; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    Ann Oncol; 2013 Apr; 24(4):965-73. PubMed ID: 23223331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver.
    Chapiro J; Duran R; Lin M; Schernthaner R; Lesage D; Wang Z; Savic LJ; Geschwind JF
    Eur Radiol; 2015 Jul; 25(7):1993-2003. PubMed ID: 25636420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
    Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):256-65. PubMed ID: 24461131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Islet cell liver metastases: assessment of volumetric early response with functional MR imaging after transarterial chemoembolization.
    Li Z; Bonekamp S; Halappa VG; Corona-Villalobos CP; Pawlik T; Bhagat N; Reyes D; Lai H; Geschwind JF; Kamel IR
    Radiology; 2012 Jul; 264(1):97-109. PubMed ID: 22627602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unresectable Intrahepatic Cholangiocarcinoma: Multiparametric MR Imaging to Predict Patient Survival.
    Pandey A; Pandey P; Aliyari Ghasabeh M; Najmi Varzaneh F; Shao N; Khoshpouri P; Zarghampour M; Fouladi DF; Liddell R; Kamel IR
    Radiology; 2018 Jul; 288(1):109-117. PubMed ID: 29584595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment?
    Georgiades C; Geschwind JF; Harrison N; Hines-Peralta A; Liapi E; Hong K; Wu Z; Kamel I; Frangakis C
    Radiology; 2012 Oct; 265(1):115-23. PubMed ID: 22891361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma.
    Hyun D; Shin SW; Cho SK; Park KB; Park HS; Choo SW; Do YS; Choo IW; Shin JW; Lim SJ
    Acta Radiol; 2015 Dec; 56(12):1437-45. PubMed ID: 25480473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation.
    Dioguardi Burgio M; Ronot M; Bruno O; Francoz C; Paradis V; Castera L; Durand F; Soubrane O; Vilgrain V
    Liver Transpl; 2016 Nov; 22(11):1491-1500. PubMed ID: 27543821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.